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Abstract. Variation in the NOS3 gene has been related to the development of restenosis. The Glu298Asp polymorphism has
previously been investigated for its effect on NO levels and the development of restenosis. However, the variability of findings
gave rise to the hypothesis that the functional significance of this polymorphism may only become manifest under conditions of
endothelial dysfunction. Since patients with the metabolic syndrome are known to have endothelial dysfunction, we aimed to
investigate if the significance of NOS3 polymorphisms may depend on the presence of the metabolic syndrome.
We examined the impact of the -949 A/G, the -716 C/T and the Glu298Asp polymorphisms in the NOS3 gene on the risk of clinical
restenosis in a previously described subpopulation of the GENDER-study, a multicenter prospective study design that enrolled
consecutive patients after successful PCI. This subpopulation consisted of 901 patients of whom sufficient data were available to
establish absence or presence of the metabolic syndrome. Of these patients, 448 had the metabolic syndrome. Clinical restenosis,
defined as target vessel revascularization (TVR), was the primary endpoint.
We demonstrated that the minor -949G, -716T and 298Asp alleles were associated with a significantly increased risk of TVR in
patients with the metabolic syndrome (HR: 1.58 [95%CI: 1.04–2.40], HR: 1.95 [95%CI: 1.02–3.70] and HR: 1.67 [95%CI: 1.09–
2.54], respectively). In the group without the metabolic syndrome we observed no association between the three polymorphisms
and TVR.
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We suggest that the metabolic alterations present in patients with the metabolic syndrome influence the functional significance of
these polymorphisms and increase the susceptibility of carriers of one of these variations in the NOS3 gene to develop restenosis
after PCI.
Keywords: Restenosis, percutaneous coronary intervention, metabolic syndrome, nitric oxide synthase, polymorphisms
1. Introduction
The frequent occurrence of restenosis is a major lim-
itation to percutaneous coronary intervention (PCI) in
patients with coronary artery disease. Patients at in-
creased risk for restenosis could benefit from alterna-
tive treatment options such as drug-eluting stents or
coronary artery bypass surgery. To be able to stratify
patients with regard to their risk of developing resteno-
sis, it is important to determine both inherited and clin-
ical factors influencing this complex and multifactorial
process.
Nitric oxide (NO) is a vasodilatory molecule known
to inhibit adhesion of platelets [27] and leukocytes [16]
to the vessel wall and to decrease proliferation and mi-
gration of vascular smooth muscle cells (VSMCs) [9],
which are all processes known to play an important
role in the development of restenosis [3]. Due to its
favourable actions in these processes, NO is likely to
play a protective role in the formation of restenosis.
Restenosis has already been related to alterations in ni-
tric oxide synthase (NOS) expression [24] and impaired
NO-dependent endothelial vasodilation [43]. In sup-
port of these observations, Piatti et al. showed a lack of
NO release after an oral glucose tolerance test (OGTT)
in patients with restenosis [26]. Since endothelial NOS
catalyses the formation of NO from L-arginine in en-
dothelial cells, polymorphisms in the NOS3 gene could
influence NO formation and thereby play a role in the
process of restenosis. The Glu298Asp polymorphism
in the NOS3 gene has previously been investigated.
However, data on its influence on NO levels and the de-
velopment of restenosis are still conflicting. Sofowora
et al. suggested that the functional significance of this
polymorphism may only become manifest under con-
ditions of endothelial dysfunction [32]. Since endothe-
lial dysfunction is an important characteristic of the
metabolic syndrome, we hypothesize that the metabol-
ic alterations present in patients with the metabolic
syndrome may influence the functional significance of
NOS3 polymorphisms. Therefore, the aim of this study
was to examine whether the -949 A/G, the -716 C/T and
the Glu298Asp polymorphisms in the NOS3 gene are
related to the risk of restenosis after PCI in patients with
and without the metabolic syndrome. The GENDER
protocol was designed to allow separate analyses in a
prespecified subgroup of patients with the metabolic
syndrome.
2. Patients and methods
The present study population has been described pre-
viously [4]. In brief, the GENetic DEterminants of
Restenosis project (GENDER) was designed to study
the association between genetic polymorphisms and
clinical restenosis. Patients were eligible for inclu-
sion if they were successfully treated for stable angina,
non-ST-elevation acute coronary syndromes or silent
ischemia by PCI. Patients treated for acute ST elevation
myocardial infarction were excluded. All patients were
treated in 4 of the 13 referral centers for interventional
cardiology in the Netherlands. The overall inclusion
period lasted from March 1999 until June 2001. We
determined the lipid profile (serum triglycerides, serum
total cholesterol, serum HDL-cholesterol) and fasting
serum glucose in a subpopulation of patients of whom
plasma was collected. The study protocol conforms to
the Declaration of Helsinki and was approved by the
Medical Ethics Committees of each participating insti-
tution. Written informed consent was obtained from
each participant before the PCI procedure.
2.1. PCI procedure
Standard angioplasty and stent placement were per-
formed by experienced operators using a radial or
femoral approach. Before the procedure, patients re-
ceived aspirin 300 mg and heparin 7500 IU. The use
of intracoronary stents and additional medication, such
as glycoprotein IIb/IIIa inhibitors, was at the discre-
tion of the operator. In case of stent implantation, pa-
tients received either ticlopidin or clopidogrel for at
least one month following the procedure depending on
local practice. During the study, no drug-eluting stents
were used.
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2.2. Follow-up and study endpoints
Follow-up lasted at least nine months, except when
a coronary event occurred. Patients were either seen
in the outpatient clinic or contacted by telephone.
Restenosis was defined by target vessel revasculariza-
tion (TVR), either by PCI or coronary artery bypass
grafting (CABG). An independent clinical events com-
mittee adjudicated the clinical events.
Events occurring within the first month were ex-
cluded from the analysis, since these events were at-
tributable mainly to sub-acute stent thrombosis or oc-
cluding dissections, and less likely to restenosis. Da-
ta were collected with standardized case-report forms
that were completed by the research coordinator at each
site. Representatives from the data-coordinating center
monitored all sites.
2.3. Genotyping
Blood was collected in EDTA tubes at baseline
and DNA was extracted following standard proce-
dures. The NOS3 -949 A/G (rs1800779), -716 C/T
(rs3918226) and the 5219 G/T (rs1799983) poly-
morphism, resulting in the amino acid substitution
Glu298Asp, were determined by a validated multilocus
genotyping assay (Roche Molecular Systems) [6]. The
Glu298Asp polymorphism has already been implicat-
ed in coronary artery disease [2] and restenosis [12,
35]. The -949 A/G polymorphism was selected on the
basis of its involvement in atherosclerotic disease [15]
and the -716 C/T polymorphism is located between the
cAMP regulatory element (nt -726 to -732) and an ac-
tivator protein-1 binding domain (nt -655 to -661) [39],
which suggests a potential involvement in gene regula-
tion.
In short, each DNA sample was amplified in a multi-
ple polymerase chain reaction (PCR) using biotinylated
primers. The PCR product pool was then hybridized to
a matching panel of sequence-specific oligonucleotide
probes, immobilized in a linear array on nylon mem-
brane strips. A colorimetric detection method based
on incubation with streptavidin-horseradish peroxi-
dase conjugate, using hydrogen peroxide and 3,3’,5,5’-
tetramethylbenzidine as substrates, was used. Opera-
tors blinded to restenosis status performed genotyping.
To confirm genotype assignments, the PCR-proce-
dure was performed in replicate on 10% of the sam-
ples. Two independent observers carried out scoring.
Disagreements (<1%) were resolved by further joint
reading, and when necessary, genotyping was repeated.
2.4. Definitions
Patients were defined as having metabolic syndrome
by presence of three or more of the following crite-
ria: 1) triglyceride level  1.7 mmol/l (150 mg/dl);
2) HDL cholesterol level < 1.04 mmol/l (40 mg/dl) in
men and < 1.3 mmol/l (50 mg/dl) in women; 3) systolic
blood pressure  130 mmHg and/or diastolic blood
pressure  85 mmHg; 4) obesity, defined as BMI >
28.8 kg/m2, which was equivalent to a waist circumfer-
ence of 102 cm in a cross-sectional study and similar to
the BMI value (28.2 kg/m2) calculated in a regression
of BMI on waist circumference in a large population
of Scottish men [18,30] and 5) fasting glucose level 
5.55 mmol/l (100 mg/dl), above which patients have
either pre-diabetes (impaired fasting glucose) or dia-
betes. This level was established by the American Di-
abetes Association and suggested as the new cut point
for identifying the lower boundary to define an ele-
vated glucose level as one criterion for the metabolic
syndrome [1,10,14].
2.5. Statistical methodology
Allele frequencies were determined by gene count-
ing, the 95% confidence intervals of the allele frequen-
cies were calculated from sample allele frequencies,
based on the approximation of the binominal and nor-
mal distributions in large sample sizes. Continuous
variables are expressed as mean ± standard deviation
and were compared by means of an unpaired, two-sided
t test. Discrete variables are expressed as counts or
percentages and were compared with a chi-square test.
The association between each of the 3 polymor-
phisms and TVR was determined using a Cox propor-
tional regression model. If less than 10 patients were
homozygous for a particular allele, the homozygotes
and heterozygotes were combined. Polymorphisms
with independent prognostic value were selected in a
multivariable regression model, also containing clinical
and procedural risk factors.
To investigate possible additive effects of haplo-
types of the NOS3 polymorphisms on TVR risk, we
analyzed haplotype effects using the THESIAS pro-
gram (www.genecanvas.org), which implements the
stochastic-EM (Expectation–Maximization) algorithm
and allows the use of Cox proportional hazards survival
regression [38]. Statistical analyses were carried out
using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL,
USA).
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3. Results
The characteristics of this patient sample have been
described previously [4]. In summary, a total of 3,146
patients had complete follow-up (99.3%) with a me-
dian duration of 9.6 months (interquartile range 3.9
months). Out of 3,146 patients 42 experienced an event
in the first 30 days and were therefore excluded from
further analysis, according to the protocol. In a pre-
viously described subpopulation of 901 patients [28],
data were sufficient to establish absence or presence of
metabolic syndrome. Of these patients, 448 (49.7%)
had metabolic syndrome ( 3 of the 5 characteristics).
The prevalence of metabolic syndrome characteristics
in patients with and without the metabolic syndrome, as
well as demographic, clinical and lesion characteristics,
are presented in Table 1. The presence of one or more
components of the metabolic syndrome was common
in both sexes: 16.3% had one component, 29.6% had
two components, 26.9% had three components, 15.9%
had four components, and 7.0% had all five compo-
nents. Except for the presence of diabetes, the preva-
lence of factors that were previously found to be relat-
ed to restenosis did not differ between the two groups.
However, patients with the metabolic syndrome had
higher insulin levels and were more frequently treated
with statins or insulin.
At follow-up 47 patients (10.5%) with the metabol-
ic syndrome versus 45 (9.9%) without the metabolic
syndrome underwent TVR. On multivariable Cox re-
gression, there was no significant increase in risk of
TVR in patients with the metabolic syndrome (HR:
1.03 [95%CI: 0.68–1.57]).
Genotyping of the -949 A/G, the -716 C/T and the
Glu298Asp (G/T) polymorphisms was successful in
96.9%, 96.7% and 96.9% of patients with the metabol-
ic syndrome and in 98.7%, 98.2% and 98.2% of those
without the metabolic syndrome, respectively. Re-
sults of the remaining patients were missing due to
lack of DNA or inconclusive genotyping. In both
groups, the frequencies of the minor -949G, -716T and
298Asp alleles were 0.37, 0.09 and 0.31, respective-
ly. The genotype distributions were consistent with
Hardy-Weinberg equilibrium and did not differ signif-
icantly between patients with the metabolic syndrome
and controls (p > 0.05).
Univariate Cox regression in patients with the
metabolic syndrome revealed a significant association
between the -949 A/G, the -716 C/T and the Glu298Asp
polymorphisms and the rate of TVR (HR: 1.58 [95%CI:
1.04–2.40] p = 0.034, HR: 1.95 [95%CI: 1.02–3.70]
p = 0.042 and HR: 1.67 [95%CI: 1.09–2.54] p = 0.018,
respectively) (Table 2).
TVR occurred more often in -949 GG homozygotes
(18.2%) than in AG heterozygotes (11.0%) or AA ho-
mozygotes (7.6%). Since only one patient was ho-
mozygous for the -716T allele, we combined homozy-
gous and heterozygous patients for this polymorphism.
This combined group had an increased risk of TVR
(17.6%) when compared to the group with the -716
CC genotype (9.2%). Homozygotes and heterozygotes
for the 298Asp allele also had a higher risk of TVR
(21.1% and 11.5%, respectively) when compared to the
Glu/Glu genotype (7.8%).
In contrast, in patients without the metabolic syn-
drome, the -949 A/G, -716 C/T and the Glu298Asp
polymorphisms were not associated with TVR (HR:
0.90 [95%CI: 0.57–1.43] p = 0.65, HR: 0.33 [95%CI:
0.10–1.08] p = 0.067 and HR: 1.02 [95%CI: 0.66–
1.59] p = 0.93, respectively). For each polymorphism,
TVR-risks were equal in the different genotype groups
(Table 2).
After adjustment for patient and intervention-related
characteristics that were previously described to be re-
lated to TVR risk, such as age, sex, hypertension, di-
abetes, current smoking, stenting, total occlusion and
residual stenosis > 20%, the -949 A/G, the -716 C/T
and the Glu298Asp polymorphisms were predictors of
TVR (HR: 1.55 [95%CI: 1.01–2.37] p = 0.043, HR:
2.05 [95%CI: 1.05–4,00] p = 0.034 and HR: 1.68
[95%CI: 1.09–2.59] p = 0.019, respectively).
As determined with haploview, the -949 A/G and
-716 C/T polymorphisms revealed significant linkage
disequilibrium (D’: 0.95) and were combined into hap-
lotypes for further analysis. The Glu298Asp poly-
morphism was excluded from this analysis due to the
lack of linkage disequilibrium between this polymor-
phism and the -949 A/G polymorphism (D’: 0.45).
In both groups, frequencies of the -949A/-716C, -
949G/-716C and -949G/-716T haplotypes were 0.62,
0.29 and 0.08, respectively. Due to its low frequen-
cy (0.007 in patients with the metabolic syndrome and
0.008 in patients without the metabolic syndrome), the
-949A/-716T haplotype was excluded from the analy-
sis. A haplotype-based risk analysis in patients with the
metabolic syndrome revealed a significant association
of the -949G/-716T haplotype with the risk for TVR
when compared to -949A/-716C, the most frequent ref-
erence haplotype (HR: 2.89 [95%CI: 1.45–5.76], p =
0.0026 (Fig. 1)).
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Table 1
Baseline and metabolic syndrome characteristics by metabolic syndrome status (N = 901)
Metabolic syndrome
Absent Present P valuea
Baseline Characteristics: N = 453 N = 448
Age (y ± SD) 63 (± 10) 61 (± 11) 0.003
BMI (kg/m2± SD) 25.4 (± 3.0) 28.7 (± 4.1) < 0.001
Female sex (%) 127 (28) 131 (29) 0.69
Diabetes Mellitus (%) 32 (7) 108 (24) < 0.001
Current smoking (%) 80 (18) 94 (21) 0.21
Stent placement (%) 376 (80) 373 (83) 0.92
Residual stenosis (%) 51 (11) 44 (10) 0.52
Total occlusion (%) 32 (7) 41 (9) 0.27
Total cholesterol (mmol/L, ± SD) 4.91 (± 1.05) 5.01 (± 1.12) 0.32
Statins (%) 231 (51) 265 (59) 0.014
Insulinb (mU/l, IQR) 12 (9) 20 (20) < 0.001
Insulin therapy (%) 13 (3) 32 (7) 0.003
Metabolic Syndrome Characteristics
BMI > 28.8 kg/m2 37 (8.2%) 207 (46.2%)
Triglycerides  1.7 mmol/L 128 (28.3%) 370 (82.6%)
HDL cholesterol < 1.04 mmol/L men and
< 1.3 mmol/L women
128 (28.3%) 324 (72.3%)
Systolic BP 130 and diastolic BP
 85 mm Hg
273 (60.3%) 383 (85.5%)
Fasting glucose 5.55 mmol/L 115 (25.4%) 329 (73.4%)
a p-value of the nonparametric Mann-Whitney test, or chi-square test.
b Insulin levels are presented as median with interquartile range (IQR).
Table 2
Cox regression of NOS3 polymorphisms in association with TVR in patients with and without the
metabolic syndrome
Metabolic syndrome Polymorphisms Number of patients TVR (%) HR (95%CI)
Present (N = 448) -949 A/G








GG 204 7.8 1.67 (1.09–2.54)
GT 192 11.5
TT 38 21.1
Absent (N = 453) -949 A/G












To test our hypothesis that the functional significance
of NOS3 polymorphisms may depend on the presence
of the metabolic syndrome, we studied the relationship
between these polymorphisms and the risk of resteno-
sis in a subpopulation of patients with the metabolic
syndrome that took part in a large follow-up study of
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Fig. 1. NOS3 haplotype effects on the risk for target vessel revascularization (TVR) in patients with (circles) and without (triangles) the metabolic
syndrome. Hazard ratios by reference to the most frequent haplotype were calculated using the THESIAS software. The -949G/-716T promoter
haplotype showed a strong association with TVR (HR: 2.89 [95%CI: 1.45–5.76], p = 0.0026), which indicates that both polymorphisms contribute
separately to the risk of TVR.
unselected, consecutive patients undergoing PCI. We
demonstrated that the -949G, -716T and 298Asp vari-
ants in the NOS3 gene were associated with a highly
increased risk of TVR after PCI in patients with the
metabolic syndrome, but not in patients without the
metabolic syndrome.
Of the -949 A/G, -716 C/T and Glu298Asp polymor-
phisms, only the Glu298Asp polymorphism has previ-
ously been investigated for its involvement in resteno-
sis. Suzuki et al. have demonstrated that carriers of
the 298Asp allele were at increased risk of developing
angiographic restenosis after stent placement (OR: 3.9
[95%CI: 1.09–13.95], after multivariate analysis) [35].
However, their population was very small (n = 85)
and consisted of relatively many patients with dia-
betes (27%). In support of their results, Gomma et
al. demonstrated in a still relatively small and selected
group of 205 stented patients, that possession of one
or more alleles of the 298Asp variant was associated
with an increased rate of angiographic restenosis after
adjusting for clinical factors (OR: 2.47 [95% CI: 1.22–
5.00]) [12]. However, Gorchakowa et al. could not con-
firm these findings and demonstrated in a similar study,
with a much larger patient number (n = 1850), that
rates of angiographic restenosis or TVR did not differ
significantly between the Glu298Asp genotypes [13].
The mechanism by which this polymorphism would
promote neointima formation remains subject to dis-
cussion. It was originally suggested that NO would
protect against restenosis because of its inhibitory role
in VSMC proliferation, adhesion of leukocytes to the
vessel wall and coagulation [9,16,27], processes known
to be involved in restenosis [3]. In addition, NO has
been shown to suppress the production of the potent
vasoconstrictors endothelin and angiotensin II, that also
induce VSMC proliferation [5,36]. Its role in resteno-
sis was further established by the observation that L-
arginine, the precursor to NO, decreases restenotic le-
sion formation in the rat [41], whereas L-NAME (NG-
nitro-L-arginine methyl ester), a non-selective NOS-
inhibitor, stimulates neo-intimal hyperplasia in the rab-
bit after balloon angioplasty [17]. In humans, intra-
mural administration of L-arginine has been shown to
reduce neointimal hyperplasia at 6 months after stent
placement [34]. Furthermore, patients with in-stent
restenosis had impaired endothelial vasodilation and a
lack of NO-release after an OGTT when compared to
patients without restenosis [26].
Although several in vitro [7] and in vivo [32,40] stud-
ies showed reduced levels of NO in Glu298Asp ho-
mozygotes, data on the functional significance of this
polymorphism are still conflicting. The 298Asp variant
has been shown to result in protein with twofold less ac-
tivity [42] and an increased susceptibility to proteolytic
cleavage [37]. However, Sessa et al. demonstrated that
the observed fragmentation was an artifact of sample
preparation for gel electrophoresis [8] and several au-
thors reported similar activity of NOS3 in the differ-
ent Glu298Asp genotypes [11,22]. Studies examining
vasodilation in response to intrabrachial injection of
acetylcholine produced conflicting results [29,31]. Fur-
thermore, flow-mediated dilation of the brachial artery
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was not affected by the Glu298Asp polymorphism [20,
23], whereas Naber et al. demonstrated a higher coro-
nary vascular resistance in 298Asp homozygotes com-
pared to that of 298Glu homozygotes at rest [25]. These
discrepancies might reflect the impact of interactions
with environmental factors, such as smoking [2].
To explain this variability, Sofowora et al. put for-
ward an interesting hypothesis. In spite of the ob-
served reduction in urinary excretion of NO in 298Asp
homozygotes, they could not demonstrate differences
between 298Asp homozygotes and 298Glu homozy-
gotes as to vascular responses to acetylcholine, glyceryl
trinitrate or phenylephrine in a healthy population [32].
Since, in contrast to their results, 298Asp homozy-
gous patients with ischemic heart disease were found
to be more sensitive to the vasoconstrictive effects of
phenylephrine, they suggested that the functional sig-
nificance of the Glu298Asp polymorphism may only
become manifest under conditions of endothelial dys-
function. In support of this possibility, Leeson et al.
demonstrated that 298Asp homozygotes had signifi-
cantly lower flow-mediated dilation than 298Glu ho-
mozygotes, only in smokers, a group known to have
endothelial dysfunction [20]. Recently, smoking car-
riers of the 298Asp allele were also found to have an
increased risk of coronary heart disease relative to non-
smokers carrying two 298Glu alleles [19].
Endothelial dysfunction is an important character-
istic of the metabolic syndrome. A study by Lteif et
al. showed that insulin resistance and systolic blood
pressure seem to be the most important determinants of
endothelial dysfunction in patients with the metabolic
syndrome [21]. Furthermore, high glucose levels are
also known to determine endothelial dysfunction. A
recent study showed that glucose downregulates NOS3
mRNA and protein expression through regulation of
mitochondrial production of reactive oxygen species
(ROS) with subsequent activation of AP-1 [33]. The
inhibitory effect of glucose on NOS3 gene transcription
was reversed by mutation of the AP-1 binding site in
the promoter region. These findings indicate a mech-
anism by which hyperglycemia could increase the sig-
nificance of NOS3 promoter polymorphisms.
Thus, if we assume that the functional significance of
NOS3 polymorphisms depends on the presence of en-
dothelial dysfunction, an explanation of our results may
be that patients with the metabolic syndrome which
carry the -949G,-716T or 298Asp alleles produce less
NO than patients without the metabolic syndrome or
carriers of the -949C, -716C or 298Glu alleles. Since
the -949G/-716T haplotype showed a stronger associa-
tion with TVR than both polymorphisms individually,
these alleles could even interact to reduce NOS3 activ-
ity in patients with the metabolic syndrome. Further
research has to be performed to test these hypotheses.
Although the variant alleles of the three NOS3 poly-
morphisms did not increase the risk of restenosis in
patients without the metabolic syndrome, the absolute
rates of restenosis did not differ between subgroups
with and without the metabolic syndrome. This im-
plies that some other yet unknown factors may have
contributed separately to the rate of restenosis in the
group without the metabolic syndrome.
4.1. Limitations of the study
One of the limitations of our study is that we did
not have waist circumference as per criteria of ATP-
III. We therefore substituted waist circumference with
variable of obesity as defined by BMI of > 28.8 kg/m 2,
this cutoff was equivalent to a waist circumference of
102 cm in a cross-sectional study and similar to the
BMI value (28.2 kg/m2) calculated in a regression of
BMI on waist circumference in a large population of
Scottish men [18,30].
In our study we lack data on NOS3 activity or NO
concentration. Abundant data is present on the func-
tionality of the Glu298Asp polymorphism. Howev-
er, little is known about a difference of NOS3 activity
between patients with and without the metabolic syn-
drome. We would like to promote research that com-
pares NOS3 activity and local NO concentrations be-
tween patients with the metabolic syndrome and con-
trols having specific genotypes of the -949 A/G, -716
C/T and Glu298Asp polymorphisms.
5. Conclusions
In conclusion, we have demonstrated that the variant
alleles of the -949 A/G, -716 C/T and Glu298Asp poly-
morphisms increase the risk of TVR in patients with
the metabolic syndrome, but not in patients without
the metabolic syndrome. We suggest that the metabol-
ic alterations in these patients influence the functional
significance of the three NOS3 polymorphisms and in-
crease the susceptibility of carriers of these variations
in the NOS3 gene to develop restenosis after PCI. Geno-
typing for these polymorphisms may lead to better risk
stratification and more tailored therapy in patients with
the metabolic syndrome to prevent TVR after PCI.
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